ADAM17 and metabolic dysfunction-associated steatohepatitis: Since TNF-alpha is upregulated in the progression of nonalcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH), it is interesting to speculate that regulating the TNF-alpha release by targeting ADAM17 could serve as a therapeutic strategy to reduce liver inflammation.